InvestSMART

Imugene Limited (ASX: IMU) - Announcements

- Current share price for IMU : $0.083

ASX company news and announcements for Imugene Limited (IMU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imugene Limited (IMU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imugene Limited (IMU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imugene Limited (IMU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$41 Application for quotation of securities - IMU 23 Jul 2025 5:31PM $0.310 $0.083 fallen by 73.23%
$41 Notice of Extraordinary General Meeting/Proxy Form 21 Jul 2025 4:01PM $0.370 $0.083 fallen by 77.57%
$41 Change of Director's Interest Notice x 3 18 Jul 2025 4:22PM $0.375 $0.083 fallen by 77.87%
$41 Application for quotation of securities - IMU 16 Jul 2025 4:20PM $0.380 $0.083 fallen by 78.16%
$41 Azer-cel new data Webinar 16 Jul 2025 12:45PM $0.365 $0.083 fallen by 77.26%
$41 Prospectus 16 Jul 2025 10:57AM $0.425 $0.083 fallen by 80.47%
$41 Imugene Capital Raising Presentation 16 Jul 2025 10:40AM $0.425 $0.083 fallen by 80.47%
$41 Proposed issue of securities - IMU 16 Jul 2025 10:39AM $0.425 $0.083 fallen by 80.47%
$41 Proposed issue of securities - IMU 16 Jul 2025 10:36AM $0.425 $0.083 fallen by 80.47%
$41 Imugene Completes $22.5M Placement and c.$15M SPP 16 Jul 2025 10:36AM $0.425 $0.083 fallen by 80.47%
$41 Trading Halt 14 Jul 2025 8:56AM $0.425 $0.083 fallen by 80.47%
$41 Two Additional Complete Responses in azer-cel Ph1b trial 14 Jul 2025 8:34AM $0.425 $0.083 fallen by 80.47%
$41 Imugene Receives $5.8m R&D Tax Refund 4 Jul 2025 9:42AM $0.415 $0.083 fallen by 80%
$41 1st Patient Dosed in Australia PD1-Vaxx neo-POLEM PhII Trial 27 Jun 2025 9:30AM $0.011 $0.083 risen by 654.55%
$41 Results of Meeting 26 Jun 2025 11:19AM $0.011 $0.083 risen by 654.55%
$41 EGM Presentation 26 Jun 2025 10:22AM $0.011 $0.083 risen by 654.55%
$41 US patent allowance for onCARlytics 18 Jun 2025 9:18AM $0.014 $0.083 risen by 492.86%
$41 Notification of cessation of securities - IMU 6 Jun 2025 4:22PM $0.016 $0.083 risen by 418.75%
$41 1st Australian site activated PD1-Vaxx Neo-POLEM Ph II trial 2 Jun 2025 9:12AM $0.015 $0.083 risen by 453.33%
$41 Dr John Byon appointed Chief Medical Officer 30 May 2025 9:57AM $0.016 $0.083 risen by 418.75%
$41 Consolidation/Split - IMU 29 May 2025 10:16AM $0.016 $0.083 risen by 418.75%
$41 Letter to Imugene Shareholders 28 May 2025 9:33AM $0.017 $0.083 risen by 388.24%
$41 Addendum to Notice of Extraordinary General Meeting 27 May 2025 6:12PM $0.017 $0.083 risen by 388.24%
$41 Notice of Extraordinary General Meeting/Proxy Form 27 May 2025 12:47PM $0.017 $0.083 risen by 388.24%
$41 Notification regarding unquoted securities - IMU 23 May 2025 4:11PM $0.017 $0.083 risen by 388.24%

126 - 150 of 1186 results

Page 6 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.